Suggested remit: To appraise the clinical and cost effectiveness of omburtamab I-131 within its marketing authorisation for treating relapsed neuroblastoma with central nervous system or leptomeningeal metastasis in children and young people.
For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
- Status:
- Suspended
- Technology type:
- Medicine
- Decision:
- Awaiting decision
- Process:
- TA
- ID number:
- 1664
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 25 January 2023 | Suspended. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 03 November 2022 | Note added to the project documents |
| 08 August 2022 | Topic selection |
| 06 September 2021 (10:00) | Scoping workshop |
| 12 July 2021 - 09 August 2021 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 24 August 2020 | Note added to the project documents |
| 21 January 2020 | In progress. Topic is proposed |
For further information on our processes and methods, please see our CHTE processes and methods manual